NCT07145918: A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
- State
- Under way
- Phase
- Phase 2
- People
- 268 planned
- Started
- 4 Aug 2025
- Primary completion
- Feb 2028
- Arms
- Placebo-Part A, Placebo-Part B
- Results
- None posted
- 4 Aug 2025: Trial started
- 28 Aug 2025: Trial registered